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Abstract: Psoriasis is a chronic immune-mediated inflammatory disease with significant medical 
and psychological comorbidities. In addition to having increased cardiovascular risk and mor-
tality, psoriasis patients are more likely to be depressed, anxious, and endorse suicidal ideation 
than the general population. These patients often have low self-esteem and feel stigmatized due 
to their skin disease, which can prevent them from pursuing relationships, dating, and attend-
ing social activities. Up to 63% of adult psoriasis patients experience psoriatic lesions on their 
genital area during their lifetime, but often do not discuss these issues with their physicians due 
to embarrassment, stigmatization, or shyness about this sensitive location. However, psoriasis in 
sensitive areas, such as the genitals, may result in quality of life impairment greater than that of 
patients with psoriasis elsewhere on their body, particularly in respect to romantic relationships, 
intimacy, and sexual function. This article evaluates the current literature regarding the impact 
of genital psoriasis on the quality of life of affected patients.
Keywords: genital psoriasis, quality of life, sexual function, sexual distress, impact
Introduction
Psoriasis vulgaris is a chronic immune-mediated systemic inflammatory disease affecting 
2%–3% of the US population.1,2 Psoriasis is often associated with scaly, well-demarcated 
papules and plaques that may appear anywhere on the body.3 Up to 63% of adult psoriasis 
patients experience psoriatic lesions in their genital area at least once during their lifetime,4 
but these localized lesions are often overlooked. Physicians often do not specifically ask 
about or examine these areas,5 and patients may be reluctant to bring up such sensitive 
topics when not prompted. Thus, almost half of all patients with genital lesions do not 
discuss their symptoms with their physician6–8 and may be undertreated.7
Although thought to be “just” a skin disease long ago, psoriasis is now well-
characterized to have various medical and psychological comorbidities. Patients with 
psoriasis have increased cardiovascular risk and mortality9,10 and are more likely to 
be depressed, anxious, and endorse suicidal ideation than the general population.11–14 
Affected patients often feel stigmatized, have low self-esteem, are embarrassed about 
their appearance,15 and suffer from functional, social, and occupational deficits.16,17 
Psoriasis can seriously impair these patients’ dating lives and relationships.18 Some 
72% of psoriasis patients feel uncomfortable about dating and 60% report that this 
disease has prevented them from pursuing an intimate relationship.19 More than 80% 
of patients believe this disease to be misunderstood by the public, and 70% feel limited 
in their ability to function socially due to their psoriasis.19 Due to the sensitive location 
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of genital psoriasis lesions, it is likely that this disease has 
great effects on quality of life, particularly in respect to 
sexual function.
Psoriasis is well-characterized to diminish quality of 
life on a variety of measures, but there is increasing interest 
in characterizing the quality of life impacts of psoriasis on 
patients with lesions within the genital area. This review 
evaluates the most current literature regarding the impact that 
genital psoriasis has on the quality of life of affected patients.
Methods
A literature search using the MEDLINE health literature 
database was conducted using the terms (“psoriasis”) AND 
(“penile” OR “penis” OR “genital*” OR “glans” OR “scro-
tal” OR “scrotum” OR “anal” OR “diaper” OR “napkin” 
OR “shaft” OR “foreskin” OR “prepuce” OR “perianal” 
OR “vulva*” OR “labia” OR “labium” OR “groin” OR 
“preputial” OR “penoscrotal”) AND (“quality”). Two inde-
pendent reviewers identified the included articles (EY and 
IS). Articles were included if they included patients with 
psoriasis affecting the genital area, discussed the quality of 
life effects or symptoms that these patients experienced due 
to their disease, and were published prior to April 8, 2018. 
Studies were excluded if they did not study genital psoriasis, 
did not discuss the quality of life effects of genital psoriasis, 
were of foreign language, were duplicates of already-included 
studies, or were reviews or meta-analyses. Study results were 
extracted using a standardized data form designed for this 
review topic.
Quality of life instruments
Dermatology Life Quality index
The Dermatology Life Quality Index (DLQI) is a 10-item 
questionnaire validated to evaluate quality of life impact and 
disability associated with skin disease.20 This questionnaire 
asks about the impact of skin disease on symptoms, self-
perception, shopping, clothing choice, social activity, physi-
cal activity, working/studying, personal relationships, sexual 
functioning, and treatment. Patients indicate how much their 
skin disease affects their life for each topic, ranging from 
“not at all” to “very much”. Each response is scored on a 
scale from 0 to 3 and summed to get a total score out of a 
maximum 30 points. A greater DLQI score indicates greater 
quality of life impairment.
Female Sexual Distress Scale
The Female Sexual Distress Scale (FSDS) is a 12-item 
questionnaire validated to evaluate sexually related personal 
distress in women.21 Patients indicate how often they are both-
ered by sexual problems, ranging from “never” to “always”. 
Each response is scored on a scale from 0 to 4 and summed 
to get a total score out of a maximum 48. A greater FSDS 
score indicates greater sexual distress, with FSDS scores ≥ 
15 indicating sexually related personal distress.
Sexual Quality of Life Questionnaire for 
Use in Men
The Sexual Quality of Life Questionnaire for Use in Men 
(SQoL-M) is an 11-item questionnaire validated to evaluate 
sexual quality of life in men with premature ejaculation or 
erectile dysfunction.22 Patients indicate their level of agree-
ment with statements regarding thoughts and feelings about 
their sex life, ranging from “completely disagree” to “com-
pletely agree”. Each response is scored on a scale from 1 
to 6, then summed, and scaled to a total score out of 100. A 
greater SQoL-M indicates better sexual quality of life, with 
men reporting no problems with sexual function having an 
average SQoL-M score of 87.22
international index of erectile Function
The International Index of Erectile Function (IIEF) is a 
15-item questionnaire validated for the assessment of male 
sexual function within the domains of erectile function, 
orgasmic function, sexual desire, intercourse satisfaction, 
and overall satisfaction.23 Patients indicate the extent to 
which their sexual function is affected within each of these 
domains. Each response is scored on a scale from 0 to 5 
and summed for a total score out of a maximum 75. An 
abridged 5-question version, the IIEF-5, can also be used 
to detect the presence of erectile dysfunction, with IIEF-5 
score ≤ 21 indicating erectile dysfunction.24 Lower scores 
on the IIEF indicate greater impairment of sexual function, 
whereas lower scores on the IIEF-5 indicate more severe 
erectile dysfunction.
Dermatologic intimacy Scale
The Dermatologic Intimacy Scale (DIS) is an 18-item 
questionnaire used to evaluate the impact of skin disease 
on intimate relationships.18 This questionnaire asks patients 
about various aspects of intimacy, including relationships, 
comfort with nudity, emotions, and self-perception. Patients 
indicate the impact of their skin disease on intimacy, ranging 
from “not at all” to “very much”. Each response is scored 
on a scale from 0 to 4, then summed to get a total score out 
of a maximum 72. A greater DIS score indicates greater 
impairment in intimacy.
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Results
A total of 46 relevant citations were identified from our lit-
erature search (Figure 1). Of these, 23 articles were selected 
for further evaluation based on the relevance of their title 
and abstract. A total of 14 articles examining the quality of 
life effects of genital psoriasis were ultimately included in 
this study.
Symptoms
Genital itch was reported by 82%–100% of genital psoriasis 
patients and was the most commonly reported symptom found 
in our analysis (Table 1).6,25,26 Itching occurred at a greater 
intensity than burning or pain and was reported to be the most 
bothersome symptom in 40% of patients.25 Another 40% of 
patients were most bothered by stinging and burning in the 
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Figure 1 Study selection for quality of life effects of genital psoriasis.
Table 1 Studies evaluating the symptoms associated with genital psoriasis
Source
Author, year
Patients, n Symptoms
Cather et al, 201725 20 Genital itch (100%), discomfort (100%), redness (95%), stinging/burning (95%), pain (85%), and scaling (75%). 
The most bothersome symptoms were reported to be itching (40%), stinging/burning (40%), and pain (20%).
Meeuwis et al, 20127 277 Patients endorse greater intensity of itch (4.2) compared with burning (3.5) and pain (2.8). Greater 
intensity of redness (5.1) compared with scaliness (3.7) and induration (2.4). intensity of all symptoms was 
significantly higher for women compared with men.
Ryan et al, 201526 354 Genital itch (86%), burning (49%), pain (44%).
Pain and burning reported significantly more frequently in females
Zamirska et al, 20086 22 itching/burning (82%)
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genital area, whereas the remaining 20% were most bothered 
by pain. Genital psoriasis lesions more characteristically 
presented with intense redness, with less scale or induration.7
effects on sexual function
Patients with genital psoriasis experience significant impair-
ments in sexual function compared with patients without 
genital involvement (Table 2). Patients with genital psoriasis 
experience decreased frequency of intercourse, avoid sexual 
relationships, and have reduced sexual desire.7,25–27 These 
patients are less comfortable with their own nudity, dating, 
and intimacy compared with patients with psoriasis lesions 
on nonsensitive areas of their body.18 Patients experience 
pain during intercourse or worsening of symptoms after 
intercourse as well.25 Women in particular experience dys-
pareunia and are distressed by the impact of genital psoriasis 
on sexual function compared with men.7,28 However, this 
distress improves with treatment targeted toward the genital 
lesions.28 Males also experience impairments in sexual func-
tion,7 but the presence of psoriasis lesions in the genital area 
was not associated with any statistical increase in erectile 
dysfunction.29,30
Table 2 Studies evaluating the effects of genital psoriasis on sexual quality of life
Source
Author, year 
Patients, n Scale Effects to sexual quality of life
Bardazzi et al, 
201630
NR iieF-5 No statistically significant difference in the rate of erectile dysfunction in psoriasis 
patients with and without genital involvement, 42% of patients with eD also 
had genital lesions. Seventy percent of patients with genital lesions did not feel 
attractive, compared with 60% overall
Cabete et al, 
201429
36 iieF-5 Rate of erectile dysfunction was higher, but not statistically significant, in psoriasis 
patients with genital involvement compared with patients without genital 
involvement
Cather et al, 
201725
20 Patient interview 
(Telephone)
impaired sexual experience during sexual activity (80%), worsening of symptoms 
after sexual activity (80%), decreased frequency of sexual activity (80%), avoidance 
of sexual relationships (75%), and reduced sexual desire (55%). impaired sexual 
experience was due to both physical effects, such as cracking or pain, and 
psychosocial effects, such as embarrassment and feelings of stigmatization.
Gupta et al, 
199727
NR “Do you believe that since 
the onset of psoriasis 
your sexual activity has 
declined?”
Greater psoriasis severity affecting the groin region was associated with a decline in 
sexual activity
Malakouti et al, 
201718
290 DiS Significantly greater intimacy impact than patients without genital involvement (DIS 
34.7 vs 27.2)
Meeuwis et al, 
201528
42 eQ-5D, eQ-vAS, DLQi, 
FSDS, SQoL-M
Females had a mean FSDS 22.8, males had a mean SQoL-M 70.7. 8 of 13 women 
(62%) had sexually related personal distress. Treatment with focus on genital lesions 
resulted in significant improvement in FSDS (8.1) by the next visit, no significant 
improvement in SQoL-M
Meeuwis et al, 
20115
277 DLQi, SQoL-M, FSDS, iieF, 
FSFi
Significantly more sexual impairment compared with patients without genital 
involvement, no difference between males and females. No significant difference in 
SQoL-M or iieF between men with and without genital involvement. Females with 
genital psoriasis had significantly greater sexual distress compared with patients 
without genital involvement (FSDS 16.1 vs 10.1) and were more likely to be sexual 
distressed (50.8% vs 32.1%). No statistically significant difference in sexual function 
was found between women with genital psoriasis and those without
Ryan et al, 
201526
354 RLSS, CeS-D, DLQi Dyspareunia (45%), worsening of genital psoriasis after intercourse (34%), 
decreased frequency of intercourse due to genital involvement (46%). Discomfort 
during intercourse reported significantly more frequently in females. Significantly 
impaired sexual function, decreased sexual frequency, increased fear of sexual 
relations compared with patients without genital involvement
Zamirska et al, 
20086
22 BDi Patients with vulvar discomfort significantly more frequently stated that psoriasis 
had a negative influence on sex life
Abbreviations: NR, not reported; PiSS, Psoriasis internalized Stigma Scale; iieF-5, international index of erectile Function-5; DiS, Dermatologic intimacy Scale; FSDS, female 
sexual distress scale; SQoL-M, Sexual quality of life questionnaire for use in men; DLQi, Dermatological Life Quality index; eQ-vAS, 5 dimension european QoL – visual 
analog scale; eQ-5D, 5 Dimension european QoL – index score; FSFi, Female Sexual Function index; RLSS, Relationship and Sexuality Scale; QeS, Questionnaire on 
experience of Skin Complaints; BDi, Beck’s Depression index; CeS-D, Center for epidemiologic Studies Depression Scale.
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Quality of life effects
Patients with genital psoriasis demonstrate significantly 
diminished overall quality of life compared with psoriasis 
patients without genital involvement (Table 3). Patients with 
genital psoriasis experience impairments in physical activ-
ity, personal relationships, work and school, and emotions.25 
Although these patients report stigmatization, two studies 
indicate that patients with genital involvement experience 
greater feelings of stigmatization than psoriasis patients 
without genital lesions,31,32 while one did not.33 Two other 
studies demonstrated that patients with genital psoriasis or 
genital discomfort experienced more depressive symptoms 
than patients without genital symptoms.6,26
Discussion
A number of studies have begun to characterize the quality of 
life impact of genital psoriasis, but these studies use various 
different quality of life instruments to capture this impact. 
Existing studies have found that genital psoriasis diminishes 
quality of life in various domains, particularly in respect to 
sexual function and distress (Table 2). Women in particular 
are distressed about genital lesions. Genital psoriasis patients 
experience frequent itching, burning, and stinging (Table 1), 
which can interfere with personal and sexual relationships. 
The quality of life impact of genital psoriasis is serious, and 
these patients are more depressed than their counterparts 
without genital involvement, who are already more depressed 
than the general healthy population (Table 3).13 However, 
more controlled studies are needed to better understand the 
full impact that genital psoriasis has on quality of life.
The use of varying quality of life instruments does not 
allow for comparison of these studies and may introduce a 
source of bias in existing analyzes. Patients are often reluc-
tant to discuss genital issues with their physicians and may 
be too embarrassed to answer fully and completely about 
genital symptoms or sexual function in certain contexts.34 
All 20 patients in the study by Cather et al25 preferred to be 
interviewed over the telephone rather than face-to-face, which 
the authors speculated to be possibly due to embarrassment 
or discomfort about discussing these sensitive topics. Thus, 
instruments not designed or validated to investigate quality 
of life impairments in this specific population of patients 
Table 3 Studies evaluating the effects of genital psoriasis on overall quality of life
Source
Author, year
Patients, n Scale Effects to overall quality of life
Alpsoy et al, 
201731
269 PiSS Significantly higher internalized stigma compared with those without genital 
involvement (PiSS 64.0 vs 59.2)
Cather et al, 
201725
20 Patient interview (telephone) impairments in mood/emotion (95%), physical activities (60%), relationships 
with friends and family (45%), and work/school (35%)
Hawro et al, 
201733
29 Feelings of Stigmatization 
Questionnaire
No statistically significant difference in level of stigmatization in psoriasis 
patients with and without genital involvement, all psoriasis patients reported 
some level of stigmatization
Meeuwis et al, 
201528
42 eQ-5D, eQ-vAS, DLQi, FSDS, 
SQoL-M
Moderate adverse effect on patients’ lives (DLQi 9.1), eQ-5D was similar 
to general population, eQ-vAS was slightly lower than general population. 
Treatment with focus on genital lesions resulted in significant improvement in 
DLQi (4.1) and eQ-5D by the next visit (mean 6 weeks, range 4–24 weeks)
Meeuwis et al, 
20115
277 DLQi, SQoL-M, FSDS, iieF, 
FSFi
Significantly worse quality of life compared with patients without genital 
involvement (DLQI 8.5 vs 5.5), significant with respect to personal relations, 
symptoms and feelings, daily activities, leisure, work and school, and treatment.
Mercuri et al, 
201743
9 PSOdisk Significantly worse quality of life than patients without genital involvement 
(PSOdisk 67.75 vs 47.5)
Ryan et al, 201526 354 RLSS, CeS-D, DLQi Significantly greater quality of life impairment determined by DLQI (8.7 vs 4.0) 
and CeS-D (13.8 vs 11.0) than patients without genital involvement
Schmid-Ott et al, 
199932
51 Six-point Likert scale of 
stigmatization experience, QeS
Significantly more patients felt stigmatized than patients without genital 
involvement with respect to self-esteem, retreat, rejection, and concealment
Zamirska et al, 
20086
22 BDi Patients with vulvar discomfort stated that itching/burning within vulva 
had negative impact on psychosocial well-being (64%). Patients with vulvar 
discomfort had higher BDi (9.6 vs 6.9) and rates of depression (39.0% vs 
19.2%) than patients without vulvar discomfort
Abbreviations: PiSS, Psoriasis internalized Stigma Scale; iieF-5, international index of erectile Function-5; DiS, Dermatologic intimacy Scale; FSDS, female sexual distress 
scale; SQoL-M, Sexual quality of life questionnaire for use in men; DLQi, Dermatological Life Quality index; eQ-vAS, 5 dimension european QoL – visual analog scale; 
eQ-5D, 5 Dimension european QoL – index score; FSFi, Female Sexual Function index; RLSS, Relationship and Sexuality Scale; QeS, Questionnaire on experience of Skin 
Complaints; BDi, Beck’s Depression index; CeS-D, Center for epidemiologic Studies Depression Scale.
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may be prone to misinterpretation and may not capture the 
true effects of genital psoriasis.
Validated instruments to measure quality of life in patients 
with scalp and nail psoriasis exist,35,36 but no such instruments 
have been validated yet for genital psoriasis. However, out-
come measure scales are currently being developed to allow 
for better characterization of the quality of life impact that 
genital psoriasis has on patients’ lives.37,38 These instruments 
may allow researchers and clinicians to better understand 
how different treatments impact quality of life in patients in 
clinical trials, an area where high-quality evidence is cur-
rently lacking.39 Genital psoriasis is uniquely challenging to 
treat because of the sensitivity and high absorption of topi-
cal agents in this area,40 so further studies using validated 
instruments are needed to assess the efficacy and safety of 
available therapies for genital psoriasis.
Affected body surface area has historically been used in 
the clinical setting to evaluate whether patients should be 
started on systemic treatment, but this paradigm has begun 
to fall out of favor. Localized psoriasis, such as involvement 
of the genitals, can significantly impair patients physically, 
socially, and emotionally, even to the point of debilitat-
ing depression. Patients with significant quality of life 
deficits due to skin disease are recommended to be started 
on systemic treatment,41,42 even without diffuse cutaneous 
involvement.
Unfortunately, genital psoriasis remains undertreated 
in the vast majority of patients. Up to two-thirds of genital 
psoriasis patients have never used treatment for their genital 
lesions, let alone systemic treatment, and almost half have 
never discussed the presence of genital lesions with their 
physician.7 Even up to 40% of patients with severe genital 
psoriasis lesions did not discuss these issues with their physi-
cian, indicating that feelings of stigmatization, shyness, or 
fear of judgment may prevent patients from inquiring about 
these problems during their healthcare visits.7 Only a quarter 
of genital psoriasis patients believe that their physicians paid 
enough attention to possible sexual problems, despite the 
evidence that all types of psoriasis affect sexual relationships 
and function.5,19
Because of the taboo nature of genital skin disease 
and sexual impairment, physicians should take a proactive 
approach and ask their psoriasis patients about symptoms 
involving the genital area. Quality of life impairment due 
to genital lesions can be improved with targeted treatment, 
so early detection of these effects may help prevent further 
functional and social deficits secondary to skin disease.28 
The development of validated quality of life instruments 
for genital psoriasis is a step in the right direction toward 
helping clinicians to assess these impacts more easily 
and may help increase our understanding of the efficacy 
of various treatments for this difficult disease.38 Genital 
psoriasis is a burdensome skin condition that significantly 
diminishes psychosocial and sexual health, and increased 
awareness of this unmet need is needed to properly care 
for these patients.
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